Nadir Hastalıkların en büyük nedeni akraba evliliği istanbulhaber.com.tr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from istanbulhaber.com.tr Daily Mail and Mail on Sunday newspapers.
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx in Combination With Opdivo as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma
1
1
Patients treated with Cabometyx in combination with Opdivo reported significantly better health-related quality of life and a lower rate of discontinuation versus sunitinib
2,3
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Cabometyx (cabozantinib) in combination with Bristol Myers Squibb s Opdivo (nivolumab) for the first-line treatment of advanced renal cell carcinoma (aRCC). The European Commission, which has the authority to approve medicines for the European Union (E.U.), will now review the CHMP recommendation and a final decision on the application in the E.U. is expected in the coming months.
Camden Clark Medical Center expands services | News, Sports, Jobs newsandsentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsandsentinel.com Daily Mail and Mail on Sunday newspapers.
SHARE
ASCO GU 2021: Genomic Landscape of Advanced Prostate Cancer In Racial Minority Populations: Real-World Experience In A Safety-Net Hospital Oncology Clinic
Published 11 February 2021
(UroToday.com) African American men have a 1.6-1.8-fold higher risk of developing prostate cancer, develop prostate cancer at a younger age, and tend to have more aggressive disease at diagnosis. Disparities in prostate cancer outcomes for these men are likely influenced by both socioeconomic and healthcare access issues, as well as genetic factors. In this study, Dr. Khashab presented genomic data derived from a retrospective analysis of patients treated at a community-focused academic healthcare system in Texas that serves a higher percentage of Hispanic and African American patients with prostate cancer.
ASCO GU 2021: Enfortumab Vedotin in Previously Treated Urothelial Cancer - Results of EV-301 & EV-201 Cohort 2 Discussion
Published 17 February 2021
(UroToday.com) In this presentation, Arlene O. Siefker-Radtke, MD from the University of Texas MD Anderson Cancer Center provided a discussion on two presentations on Enfortumab Vedotin (EV) in previously treated urothelial cancer. She first reviewed the results of EV-301 (Abstract 393) which provided level 1 evidence of overall survival benefit with EV compared to single-agent chemotherapy in patients who progressed on platinum chemotherapy and immune checkpoint blockade. The trial schema and relevant overall survival data are re-shown below. EV also demonstrated a progression-free survival benefit and improved overall response rates to 41% from 18% with single-agent chemotherapy.